| Kathleen M Myers, MD | |
|
2211 Ne 139th St, Vancouver, WA 98686-2742 | |
| (360) 487-1400 | |
| Not Available |
| Full Name | Kathleen M Myers |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 2211 Ne 139th St, Vancouver, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164446498 | NPI | - | NPPES |
| 8157190 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD00031425 (Washington) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040220000099 |
News Archive
The presence - or absence - of complications following surgery is a strong indicator of which patients are likely to be readmitted to the hospital in the 30 days following their procedure, according to a study published today in JAMA Surgery.
Researchers reported today on a procedure that can preserve fertility and potentially save the lives of women with a serious pregnancy complication called placenta accreta. Results of the new study presented at the annual meeting of the Radiological Society of North America showed that placement of balloons in the main artery of the mother's pelvis prior to a Caesarean section protects against hemorrhage and is safe for both mother and baby.
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
With a relatively minor genetic change, a new treatment developed by researchers at the Georgia Institute of Technology and Emory University appears to stop replication of both flu viruses and the virus that causes Covid-19.
› Verified 9 days ago
| Entity Name | Public Hospital District No. 2, Klickitat County, Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952483653 PECOS PAC ID: 4981592144 Enrollment ID: O20040309000490 |
News Archive
The presence - or absence - of complications following surgery is a strong indicator of which patients are likely to be readmitted to the hospital in the 30 days following their procedure, according to a study published today in JAMA Surgery.
Researchers reported today on a procedure that can preserve fertility and potentially save the lives of women with a serious pregnancy complication called placenta accreta. Results of the new study presented at the annual meeting of the Radiological Society of North America showed that placement of balloons in the main artery of the mother's pelvis prior to a Caesarean section protects against hemorrhage and is safe for both mother and baby.
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
With a relatively minor genetic change, a new treatment developed by researchers at the Georgia Institute of Technology and Emory University appears to stop replication of both flu viruses and the virus that causes Covid-19.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen M Myers, MD 6312 Sw Capitol Hwy # 502, Portland, OR 97239-1938 Ph: (503) 464-9034 | Kathleen M Myers, MD 2211 Ne 139th St, Vancouver, WA 98686-2742 Ph: (360) 487-1400 |
News Archive
The presence - or absence - of complications following surgery is a strong indicator of which patients are likely to be readmitted to the hospital in the 30 days following their procedure, according to a study published today in JAMA Surgery.
Researchers reported today on a procedure that can preserve fertility and potentially save the lives of women with a serious pregnancy complication called placenta accreta. Results of the new study presented at the annual meeting of the Radiological Society of North America showed that placement of balloons in the main artery of the mother's pelvis prior to a Caesarean section protects against hemorrhage and is safe for both mother and baby.
UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
With a relatively minor genetic change, a new treatment developed by researchers at the Georgia Institute of Technology and Emory University appears to stop replication of both flu viruses and the virus that causes Covid-19.
› Verified 9 days ago
Dr. Andrew Douglass Zechnich, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3400 Main St, Vancouver, WA 98663 Phone: 360-696-5232 Fax: 360-696-5228 | |
Jeff S Brent, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. Erin Meadows, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 559-250-7564 | |
Megumi S Ketcham, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1000 | |
Dr. Jamie Mcginnity, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1000 | |
George T Lin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1400 | |
Daniel M Bissell, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1400 |